FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a method of treating cancer expressing mutant EZH2.
EFFECT: invention provides effective treatment of cancer associated with expression of mutant EZH2.
15 cl, 17 ex, 7 tbl, 15 dwg
Title | Year | Author | Number |
---|---|---|---|
HUMAN EZH2 INHIBITORS AND METHODS OF APPLICATION THEREOF | 2011 |
|
RU2618475C2 |
HUMAN EZH2 INHIBITORS AND METHODS FOR APPLICATION THEREOF | 2011 |
|
RU2765155C2 |
COMBINED THERAPY FOR CANCER TREATMENT | 2013 |
|
RU2699546C2 |
METHODS OF TREATING CANCER | 2013 |
|
RU2677276C2 |
SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2629118C2 |
ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2632193C2 |
COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
ANTIBODY-DRUG CONJUGATES INCLUDING ANTIBODY AGAINST HUMAN DLK1 AND THEIR USE | 2020 |
|
RU2801630C2 |
SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
ANTI-FcRH5 ANTIBODIES | 2014 |
|
RU2687132C2 |
Authors
Dates
2019-10-28—Published
2013-03-12—Filed